Claims
- 1. A method of producing a genetic mutant transfected with at least three different nucleic acid constructs, the method comprising:a) transfecting a unicellular diploid organism with first and second nucleic acid constructs, said first construct comprising a first selectable marker flanked by nucleotide sequences complementary to 5′ and 3′ flanking regions of a first allele of a genetic locus to be replaced, and said second construct comprising a second selectable marker flanked by nucleotide sequences complementary to 5′ and 3′ flanking regions of a second allele of the genetic locus to be replaced under conditions to promote deletion and replacement of said genetic locus by said DNA sequences; b) selecting for replacement and loss of said genetic locus from the genome of said unicellular diploid organism by detecting expression of both said different marker genes; c) isolating a genetic mutant of said unicellular diploid organism that expresses both said selectable marker genes, said mutant having lost both said alleles of said genetic locus via replacement with both said selectable markers; and d) further transfecting said genetic mutant of said unicellular diploid organism with a third nucleic acid construct defining a DNA sequence which encodes an immunogen.
- 2. A genetic mutant of a unicellular diploid organism produced according to the method of claim 1.
- 3. A genetic mutant of a unicellular diploid organism, the genome of which is devoid of a naturally-occurring genetic locus that modulates virulence of said organism in a host, said genetic locus having been replaced by at least two different exogenous selectable marker genes, said genetic mutant further comprising a third exogenous DNA sequence encoding an immunogen.
- 4. The mutant of claim 3 wherein said genetic locus further modulates persistence of said organism in said host in vivo and is not required for growth of said organism in vitro.
- 5. The mutant of claim 3 wherein said unicellular diploid organism is a protozoa.
- 6. The mutant of claim 3 wherein said protozoa is a parasitic protozoa.
- 7. The mutant of claim 6 wherein said parasitic protozoa is a member of the genus Leishmania.
- 8. The mutant of claim 3 wherein said exogenous DNA sequence encoding said immunogen is chromosomal or extrachromosomal.
RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 08/762,529, filed Dec. 9, 1996, now allowed U.S. Pat. No. 5,955,333, which is a file-wrapper continuation of U.S. patent application Ser. No. 08/489,701, filed Jun. 13, 1995, which is a file-wrapper continuation of U.S. patent application Ser. No. 08/066,718, filed May 24, 1993, which is a continuation-in-part of U.S. patent application Ser. No. 07/744,313 filed Aug. 13, 1991, all abandoned the contents of which are hereby incorporated by reference.
GOVERNMENT FUNDING
This invention was supported by NIH grant numbers Al-21903 and Al-29646 and the government has certain rights to the invention.
Non-Patent Literature Citations (3)
Entry |
Johnston D.A. et al. “Genomics and the biology of parasites”. BioEssays vol. 21: pp. 131-147, Feb. 1999.* |
Afrin, F. et al, “Isotype profiles of Leishmania donovani-infected Balb/c mice:” J. Parasitology, vol. 84, pp. 743-748, Aug. 1998.* |
Kwiatkowski, D., “Development of a malaria vaccine”, The Lancet, vol. 350, pp. 1606-1701, Dec. 1997 |
Continuations (3)
|
Number |
Date |
Country |
Parent |
08/762529 |
Dec 1996 |
US |
Child |
09/236149 |
|
US |
Parent |
08/489701 |
Jun 1995 |
US |
Child |
08/762529 |
|
US |
Parent |
08/066718 |
May 1993 |
US |
Child |
08/489701 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07/744313 |
Aug 1991 |
US |
Child |
08/066718 |
|
US |